When do biologic drug patents expire and when will biosimilars launch?

United States Patent 10,543,283: How Strong Are the CNS Intranasal “Guanidinoglycoside–Biologic” Claims?

US Patent 10,543,283 claims two method families that converge on the same technical concept: intranasal delivery of a conjugate that combines (i) one or more guanidinoglycosides (defined to include covalently linked variants of aminoglycoside-derived guanidino species) with (ii) a biologic used to treat CNS/neurological disorders, including monoclonal antibodies and a long enumerated roster of antibodies.

The claims are broad at the level of the treatment method and the biologic class, but they narrow through a constrained conjugate definition and an intranasal administration route. As written, the patent’s enforceability is likely to depend on (1) whether guanidinoglycoside-biologic intranasal conjugates are already disclosed in prior art and (2) whether specific guanidino-aminoglycoside conjugation and intranasal administration combinations were known in a way that would render the asserted “increase uptake in brain” approach obvious.

What exactly does US 10,543,283 claim?

Claim set overview

The claims define two methods:

Treating a CNS/neurological disorder by intranasally administering a therapeutically effective amount of a conjugate containing:
- one or more guanidinoglycosides
- and a biologic useful for treating the disorder
- with the biologic specifically including monoclonal antibodies / immunoglobulin fractions in dependent claims.
Increasing cellular uptake of the biologic by:
- coupling the biologic to guanidinoglycosides to form a conjugate
- and intranasally administering an effective amount to the brain.

Core structural limitations in the claims

Key elements that drive claim scope and validity risk:

Route: intranasal administration (claims 1, 13 and dependents).
Conjugate: the guanidinoglycoside is present and is optionally covalently bound to the biologic, either directly or via a linker (claims 2–3, 14–15).
Linker breadth: linker can include hydrocarbon, PEG, oligoamide, oligoester, and functionalized or chemically/enzymatically cleavable moieties (claims 3, 15).
Biologic: monoclonal antibody or purified immunoglobulin fraction (claims 4, 16).
Biologic enumeration: extensive list of specific antibodies (claims 5 and 17; note that lists overlap but are not identical in the claim text you provided).
Disorder list: wide CNS/neurological set including Alzheimer’s and Parkinson’s and many others (claims 7–9, 18).
Guanidinoglycoside scope: defined as an aminoglycoside antibiotic in claim 10; and includes a long roster of specific “guanidino-” variants (claim 11 / 20).
Molecular weight constraint: biologic has MW > 27,500 Da (claims 12, 21).

Practical claim map

Claim group	Required steps / limitations	What is broadened	What is narrowed
Claims 1–12 (treatment)	intranasal administration of conjugate; biologic treats CNS disorder	any CNS/neurological disorder from list; any biologic from antibody/immunoglobulin universe	guanidinoglycoside-biologic conjugate; covalent/linker options; enumerated antibody options; aminoglycoside-guanidino definition; MW >27,500 in dependent
Claims 13–21 (uptake enhancement)	coupling biologic to guanidinoglycosides; intranasal administration to brain	“cellular uptake” is a mechanism hook with broad application to biologics	still requires conjugate and intranasal administration; same guanidinoglycoside and linker constraints

How novel is the concept?

The claimed concept is a three-part combination

From a patentability perspective, US 10,543,283 is not claiming:

intranasal biologic delivery in general, by itself, or
guanidinoglycosides in general, by themselves, or
bioconjugation/linker chemistry in general, by itself.

Instead, it claims a specific combination:

guanidinoglycoside–biologic conjugate (with optional covalent linking and specified linker families),
administered intranasally, and
targeted at brain/CNS disease treatment or increased cellular uptake.

Where novelty is likely to be attacked

A typical obviousness attack for this patent would argue that each element is known and their combination would have been obvious to try for intranasal brain delivery.

The highest-risk claim aspects are:

Route choice: intranasal delivery for CNS biologics is a known delivery approach in the art; it is often used to bypass the BBB for CNS targeting.
Conjugation approach: aminoglycoside-derived guanidino moieties are associated in the literature with enhanced cellular interaction/uptake via charge-driven uptake pathways.
Mechanism claim (uptake): claim 13 explicitly recites “increasing cellular uptake,” which invites obviousness arguments where prior art already measures or implies enhanced uptake.

Where novelty may still be defensible

If the guanidinoglycoside is specifically and consistently tied to:

guanidino-aminoglycoside identities (claims 10–11, 19–20),
conjugation to antibodies/immunoglobulins (claims 4, 16),
and intranasal brain delivery as the administration route (claims 1, 13),

then the patent could defend novelty on the basis that the precise pairing of these defined guanidino-aminoglycosides with large biologics via conjugation and intranasal delivery had not been taught together.

What do the guanidinoglycoside and linker limitations do to claim scope?

Guanidinoglycoside limitations are both enabling and constraining

Claims 10, 11 and 19, 20 restrict guanidinoglycosides to aminoglycoside antibiotics and specify multiple “guanidino-” derivatives (e.g., guanidino-amikacin, guanidino-gentamicin, guanidino-kanamycin, guanidino-neomycin, guanidino-netilmicin, guanidino-streptomycin, guanidino-paromomycin, guanidino-dibekacin, guanidino-arbekacin, guanidino-isepamicin, guanidino-sisomicin, guanidino-ribostamycin, guanidino-tobramycin).

This does two things:

It prevents an easy “any guanidino compound” argument.
It narrows the set of candidate prior art to documents that specifically disclose guanidino-aminoglycoside conjugates.

Linker clause broadens chemistry outcomes

The linker language (claims 3 and 15) is broad:

hydrocarbon
PEG
oligoamide
oligoester
functionalized moieties
and chemically/enzymatically cleavable moieties

This breadth increases the chance that a design-around is still covered even if a competitor uses different linker types.

How strong are the antibody and disease lists?

Antibody selection is partly enumerative

Claims 5 and 17 enumerate many antibodies (examples include aducanumab, bapineuzumab, crenezumab, gantenerumab, ponezumab, plus others such as rituximab, trastuzumab, cetuximab, bevacizumab, and many immune oncology antibodies listed).

From an enforcement standpoint:

Enumeration can strengthen infringement positioning for those exact antibody conjugates.
It can also limit literal infringement for antibodies not listed unless claim construction interprets the lists as exemplary versus exclusive.

In the provided dependent claim text, the “selected from the group consisting of …” structure suggests closed lists in those dependents.

Disease list supports broad clinical positioning

Claim 7 provides a wide disease catalog: Alzheimer’s disease, Parkinson’s disease, ALS, Friedreich’s ataxia, Huntington’s disease, Lewy body disease, cerebrovascular disorders, frontotemporal dementia, motor dysfunction, eating and sleep disorders, schizophrenia, brain tumors, ataxia, West Nile virus encephalitis, Neuro-AIDS, brain and spinal cord injury, and multiple sclerosis.

Dependents 8 and 9 isolate Alzheimer’s and Parkinson’s.

The list breadth matters because it reduces the likelihood that prior art narrow to one disease would avoid an invalidation argument on “different disorder” grounds.

Patent landscape: what competitors likely look for

A proper landscape for US 10,543,283 depends on locating:

earlier patent filings on intranasal delivery of antibodies/biologics for CNS indications
earlier patent filings on guanidino-aminoglycosides as delivery enhancers or conjugates
earlier patents on bioconjugation of aminoglycoside-derived moieties to antibodies
earlier combinations of both (intranasal administration and guanidino-aminoglycoside conjugates)

On the claim text alone, the litigation and freedom-to-operate question typically narrows to one of these three buckets:

Direct anticipation: a single prior art document discloses intranasal brain delivery of a guanidino-aminoglycoside conjugate with an antibody/immunoglobulin.
Obviousness: prior art discloses intranasal antibody delivery plus separately discloses guanidino-aminoglycoside conjugation as a cellular uptake enhancer, making the combination an obvious optimization.
Partial anticipation plus legal gap: partial disclosures exist (e.g., intranasal delivery with different uptake enhancers) but the claimed guanidino-aminoglycoside identities and conjugate structure create a difference that defeats anticipation and may limit obviousness.

Critical validity assessment by claim feature

Claim 1 (treating CNS disease via intranasal guanidinoglycoside-biologic conjugate)

Most attacked elements

intranasal administration to deliver biologics to the brain,
the idea that conjugating to a uptake enhancer increases CNS delivery,
the generality of “biologic useful for treating” a wide set of disorders.

Most defensible elements

specific definition of guanidinoglycoside as guanidino-aminoglycoside antibiotic variants (through dependents 10–11),
requirement that the conjugate includes guanidinoglycosides and a biologic,
and (if claim construction applies) covalent coupling and linker specifics in dependents.

Net: Claim 1 is likely broad enough to be invalidated if any earlier document discloses the same conjugate class and route for any CNS disorder.

Claims 2–3 (covalent bond and linker types)

These are medium strength because:

the linker list is broad, reducing competitor freedom,
but the covalent bond requirement narrows prior art that only used noncovalent complexation.

Net: Stronger than Claim 1 if prior art relies on noncovalent formulations.

Claims 4–6 (monoclonal antibody and selected antibody subsets)

The dependent claims help enforcement by anchoring the biologic to an antibody/immunoglobulin frame, but novelty may be weakened if prior art includes intranasal antibody delivery generally.

Claims 7–9 (CNS disorder selection including Alzheimer’s, Parkinson’s)

Because the disease list is broad and includes high-profile indications, prior art referencing CNS intranasal biologic delivery could map easily to at least one of these.

Claims 10–11 (guanidino-aminoglycoside identities)

This is where the patent may hold the line. A competitor can argue prior art used different aminoglycoside-derived guanidino species or different guanidine-containing uptake enhancers.

Claims 12 (biologic MW > 27,500 Da)

This is likely a weak differentiator if antibodies are already the paradigm biologic class for the patent. MW >27,500 will usually be satisfied by typical IgG formats and many fragments depending on how MW is calculated.

Claims 13–15 (uptake enhancement method + covalent linker)

Mechanism claims can be attacked if uptake enhancement is inherent or already shown in prior art intranasal delivery of antibody conjugates.

Net: The “increase cellular uptake” step does not add much if prior art demonstrates increased uptake from similar conjugation chemistry.

Claims 16–18 (monoclonal antibody and disease list)

These replicate the earlier disease and antibody framing.

Claims 19–21 (guanidino-aminoglycoside identities; MW constraint)

This repeats the differentiators from 10–12.

Design-around and infringement risk

Most plausible design-arounds

Avoid intranasal route
If a competitor uses parenteral routes, intrathecal delivery, or alternative nasal formulations that do not fall within “intranasal administration,” it could shift infringement away from claims 1 and 13.
Use different uptake enhancer chemistry
If a competitor uses non-guanidino aminoglycosides or uses guanidine-containing motifs not matching the specified guanidinoglycoside/aminoglycoside antibiotic definitions, it can evade claims tied to claim 10–11 and 19–20.
Use noncovalent association
If a competitor formulates the biologic with guanidinoglycosides via ionic interaction rather than covalent binding, it can potentially avoid dependent claims 2 and 14, though Claim 1 and Claim 13 still require a “conjugate comprising” which may be construed to include covalent and noncovalent depending on specification and claim construction.
Use antibody not in the enumerated closed list in the dependents
That may avoid dependent claims 5–6 and 17, but would not avoid claim 1 or claim 13 unless the main claim construction requires those specific antibody identities.

What is likely hard to avoid

If a competitor’s product:

is an antibody/immunoglobulin,
conjugated to guanidino-aminoglycoside species listed in the dependents,
administered intranasally to target CNS uptake, then the patent’s claim set is likely to remain a central infringement risk.

Key Takeaways

US 10,543,283 claims a method-of-use centered on intranasal delivery of guanidinoglycoside–biologic conjugates to treat CNS/neurological disorders or increase brain cellular uptake.
The patent is structurally anchored by guanidino-aminoglycoside identities (dependent claims 10–11 / 19–20) and optionally by covalent linkage and broad linker families (claims 2–3 / 14–15).
Enforceability will likely hinge less on the disease list and more on whether prior art discloses the same conjugate class + intranasal route + antibody/immunoglobulin pairing.
Competitors’ most credible defenses are route changes, different uptake enhancer chemistry, noncovalent association, and staying outside the listed antibody sets for the closed-group dependents.

FAQs

1) Does the patent require covalent attachment of the guanidinoglycoside to the biologic?

Not in the broadest independent method text you provided; covalent binding appears in the dependent claims (claims 2 and 14). The broader claim requires a conjugate, and whether that necessarily implies covalent linkage depends on claim construction tied to the specification.

2) Which parts most constrain the guanidinoglycoside chemistry?

Claims 10–11 (and 19–20) constrain the guanidinoglycoside to guanidino-aminoglycoside antibiotics and explicitly list many guanidino derivatives.

3) Are the antibody choices broad or limited?

The dependent claims include closed “selected from the group consisting of” lists for specific antibodies (claims 5 and 17), but the independent method requires only that the biologic is useful for treating CNS/neurological disorders, with antibody status added in dependent claims (claims 4 and 16).

4) How does the “molecular weight > 27,500 Da” limit affect enforcement?

It likely excludes very small fragments but will typically be satisfied by most IgG-scale antibodies or large immunoglobulin fractions, depending on how the MW is defined in the relevant claim interpretation.

5) What is the key vulnerability of the patent in validity challenges?

If prior art already teaches intranasal delivery of antibodies to the brain and separately teaches guanidino-aminoglycoside conjugation as an uptake enhancer, an obviousness challenge can target the combination even if the exact disease and antibody are not identical.

References

[1] United States Patent and Trademark Office. US Patent 10,543,283 (publication and claim set as provided in the prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,543,283	2037-09-06
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	10,543,283	2037-09-06
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	10,543,283	2037-09-06
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	10,543,283	2037-09-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Summary for Patent: 10,543,283